Form 4: Corcept Therapeutics Director Acquires Stock Options

David L. Mahoney, a Director at Corcept Therapeutics, acquired stock options for 12,500 shares.

Summary

• David L. Mahoney, a Director at Corcept Therapeutics Inc. (CORT), acquired 12,500 stock options on May 21, 2026.
• The stock options have an exercise price of $59.69 per share.
• These options are exercisable ratably in equal monthly installments over a one-year period, starting from May 21, 2026, contingent upon continued service.
• The options expire on May 21, 2036.
• Following this transaction, Mahoney beneficially owns 12,500 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard incentive grant to a director rather than a direct purchase of stock.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule over one year suggests a commitment to continued service.
• The exercise price is set, providing a clear benchmark for potential future gains.

Negatives

• This is a grant of options, not a purchase of shares, meaning no immediate capital was invested by the director.
• The value of the options is contingent on the stock price increasing above the exercise price of $59.69.

Risks

• The value of the acquired options is subject to market volatility and the company's future performance.
• Continued service is a condition for vesting, implying a risk of forfeiture if service is terminated.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's stock performance, as the options will only be valuable if the stock price rises above the exercise price.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology and pharmaceutical sectors, often used as a long-term incentive to align management and director interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with potential future stock price appreciation.
• Employees: This type of grant is typical for executive and director compensation, reinforcing standard corporate practices.
• Management: The director's continued service is tied to the vesting of these options, encouraging ongoing commitment.

Next Steps

• The director's continued service will determine the vesting of the stock options.
• The options can be exercised between the vesting dates and the expiration date of May 21, 2036.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Stock Options, Insider Trading, Beneficial Ownership, David L. Mahoney, Director, SEC Filing